ストックスクリーナーアプリを入手
0.7746
3.05%
-0.0244
アフターアワーズ：
.77
-0.0046
-0.59%
前日終値:
$0.799
開ける：
$0.78
24時間の取引高:
176.56K
Relative Volume:
0.03
時価総額：
$6.56M
収益：
-
当期純損益:
$-16.28M
株価収益率:
-0.0557
EPS:
-13.91
ネットキャッシュフロー:
$-13.75M
1週間 パフォーマンス:
-8.76%
1か月 パフォーマンス:
-18.97%
6か月 パフォーマンス:
-69.50%
1年 パフォーマンス:
-84.93%
1日の値動き範囲:
$0.76
$0.78
1週間の範囲:
$0.7101
$0.87
52週間の値動き範囲:
$0.7101
$7.50
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
名前
Pasithea Therapeutics Corp
セクター
電話
(702) 514-4174
住所
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
KTTA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.7746 | 6.56M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Pasithea Therapeutics Corp (KTTA) 最新ニュース
Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board - GlobeNewswire
Nature Journal Author Joins Pasithea to Advance Revolutionary IBD Treatment Research - Stock Titan
Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated - MSN
Pasithea reports promising phase 1 results for cancer drug By Investing.com - Investing.com South Africa
Pasithea reports promising phase 1 results for cancer drug - Investing.com
Pasithea Therapeutics Reports Promising Interim Results for PAS-004 in Phase 1 Trial for Refractory Solid Tumors at ASCO 2025 - Nasdaq
Pasithea Therapeutics Presents Updated Interim Data from - GlobeNewswire
Breakthrough Cancer Drug Shows 15% Tumor Shrinkage in Melanoma and Pancreatic Cancer Patients in Phase 1 Trial - Stock Titan
Pasithea’s PAS-004 shows promise in inflammatory disease study - Investing.com Australia
Pasithea Therapeutics Announces Preclinical Data That Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases - marketscreener.com
Pasithea Therapeutics Reports Promising Preclinical Data for PAS-004 as a Novel MEK Inhibitor for Inflammatory Diseases - Nasdaq
Pasithea Therapeutics Announces Preclinical Data that Shows - GlobeNewswire
Breakthrough: Novel IBD Drug Outperforms FDA-Approved Treatment in Targeting Key Inflammation Pathway - Stock Titan
Neurofibromatosis Type 1 Market Set to Witness Significant Growth During the Study Period (2020–2034) Driven by Advances in Treatment | DelveInsight - GlobeNewswire Inc.
Pasithea to commence Phase I/Ib trial of neurofibromatosis type 1 therapy - Yahoo Finance
Pasithea Therapeutics CEO sells shares worth $792 - Investing.com
Pasithea Therapeutics Announces Initiation Of Phase 1/1B Study Of Pas-004 In Adult Nf1 Patients And Activation Of First Clinical Trial Site - marketscreener.com
Pasithea Therapeutics Announces Initiation of Phase 1/1B - GlobeNewswire
Phase 1/1b Trial: Pasithea's Once-Daily NF1 Drug Could Outperform Current Treatments - Stock Titan
Pasithea Therapeutics Raises $6.3 Million in Stock Offering - TipRanks
Pasithea Therapeutics Closes $5 Million Public Offering to Advance Development of PAS-004 for Neurofibromatosis and Cancer Indications - Nasdaq
Pasithea Therapeutics Announces Closing of $5 Million Public Offering - GlobeNewswire
Pasithea Therapeutics 3.57M share Secondary priced at $1.40 - Yahoo Finance
Pasithea Therapeutics Announces Pricing Of $5 Million Public Offering - marketscreener.com
Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated By Stocktwits - Investing.com India
Pasithea Therapeutics Prices $5 Million Public Offering - marketscreener.com
Pasithea Therapeutics announces interim data from Phase 1 trial of PAS-004 - TipRanks
Pasithea Therapeutics Announces Pricing of $5 Million Public Offering - The Manila Times
Pasithea Therapeutics (KTTA) Skyrockets: Stock Soars Over 115% in Morning Trade - apnakal
$5M Public Offering: Pasithea Therapeutics Advances MEK Inhibitor Drug for Rare Disease Treatment - Stock Titan
Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results - Benzinga
Pre-market Movers: KTTA, SXTC, GLMD, TCMD... - RTTNews
Pasithea reports promising data on cancer drug PAS-004 - Investing.com
Pasithea reports promising data on cancer drug PAS-004 By Investing.com - Investing.com South Africa
Pasithea Therapeutics Reports Promising Phase 1 Trial Results for PAS-004, Demonstrating Up to 91% pERK Inhibition and Tumor Volume Reduction in Advanced Cancer Patients - Nasdaq
Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004 - GlobeNewswire
Phase 1 Trial Reveals 91% Target Success: New Cancer Drug Shows Promise in Pancreatic Cancer Patient - Stock Titan
Pasithea Therapeutics Files For Offering Up To 3.2 Mln Common Shares Together With Warrants, Says SEC Filing - marketscreener.com
AMD Stock Signals Strong Buy Ahead of Earnings - The Globe and Mail
Pasithea completes enrollment in cohort 6 of Phase 1 trial of PAS-004 - TipRanks
Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients - The Manila Times
Pasithea's Cancer Drug Trial Hits Key Milestone: Latest Results from Advanced Treatment Study - Stock Titan
Pasithea Therapeutics Announces Acceptance of Abstract for ASCO 2025 Presentation on PAS-004 Clinical Trial Data - Nasdaq
Pasithea Therapeutics to Present Updated Data from Ongoing - GlobeNewswire
New PAS-004 Cancer Trial Data Shows Clinical Activity and Safety Profile | KTTA Stock News - Stock Titan
Pasithea Therapeutics (NASDAQ:KTTA) Shares Down 16.9% – Here’s What Happened - Defense World
Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing C - Asianet Newsable
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing Cohort - MSN
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Pasithea Therapeutics progresses with cancer drug trial By Investing.com - Investing.com South Africa
Pasithea Therapeutics Corp (KTTA) 財務データ
収益
当期純利益
現金流量
EPS
Pasithea Therapeutics Corp (KTTA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Marques Tiago | Chief Executive Officer |
May 12 '25 |
Sale |
0.82 |
960 |
792 |
40,001 |
2.13%
1.01%
大文字化:
|
ボリューム (24 時間):